JP2025512987A5 - - Google Patents
Info
- Publication number
- JP2025512987A5 JP2025512987A5 JP2024559383A JP2024559383A JP2025512987A5 JP 2025512987 A5 JP2025512987 A5 JP 2025512987A5 JP 2024559383 A JP2024559383 A JP 2024559383A JP 2024559383 A JP2024559383 A JP 2024559383A JP 2025512987 A5 JP2025512987 A5 JP 2025512987A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- apoa
- lipid
- formulation according
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263328210P | 2022-04-06 | 2022-04-06 | |
| US63/328,210 | 2022-04-06 | ||
| PCT/IB2023/000183 WO2023194798A1 (en) | 2022-04-06 | 2023-04-06 | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512987A JP2025512987A (ja) | 2025-04-22 |
| JP2025512987A5 true JP2025512987A5 (https=) | 2026-04-14 |
Family
ID=86732365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559383A Pending JP2025512987A (ja) | 2022-04-06 | 2023-04-06 | 脂質結合タンパク質に基づく複合体を使用して白血球増加、内皮機能不全、および心臓炎を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250255931A1 (https=) |
| EP (1) | EP4504233A1 (https=) |
| JP (1) | JP2025512987A (https=) |
| KR (1) | KR20240171131A (https=) |
| CN (1) | CN119317440A (https=) |
| AU (1) | AU2023251245A1 (https=) |
| CA (1) | CA3247588A1 (https=) |
| IL (1) | IL316100A (https=) |
| MX (1) | MX2024012302A (https=) |
| WO (1) | WO2023194798A1 (https=) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| CA2185450A1 (en) | 1994-03-22 | 1995-09-28 | Patrick Tso | Eating suppressant peptides |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| DE60117781T2 (de) | 2000-04-21 | 2006-11-23 | Amgen Inc., Thousand Oaks | Peptidderivate des apolipoproteins-a1/aii |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| BR0115257A (pt) | 2000-11-10 | 2003-08-12 | Proteopharma Aps | Análogos de apolipoproteìna |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| DE60226881D1 (de) | 2001-08-20 | 2008-07-10 | Zlb Bioplasma Ag | High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| JP2006507223A (ja) | 2002-05-17 | 2006-03-02 | エスペリオン セラピューティクス，インコーポレイテッド | 脂質代謝異常疾患の治療方法 |
| EP1545576A2 (en) | 2002-07-30 | 2005-06-29 | Esperion Therapeutics Inc. | Methods of using non-human animal apoliprotein a-i protein |
| TWI433693B (zh) | 2003-02-14 | 2014-04-11 | Childrens Hosp & Res Ct Oak | 親脂藥物傳送媒介物及其使用方法 |
| KR101185609B1 (ko) | 2004-07-16 | 2012-09-24 | 트러스티즈 오브 터프츠 칼리지 | 아포리포단백질 ａ１ 미메틱 및 이의 용도 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1917278A2 (en) | 2005-08-26 | 2008-05-07 | Cerenis Therapeutics Holding SA | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| US8541236B2 (en) | 2006-12-08 | 2013-09-24 | University Of Washington | Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls |
| US20080293102A1 (en) | 2007-02-28 | 2008-11-27 | Cerenis Therapeutics Holding, S.A. | Compositions and methods for producing apolipoprotein |
| US9173890B2 (en) | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| WO2009055538A1 (en) | 2007-10-23 | 2009-04-30 | The Cleveland Clinic Foundation | Oxidant resistant apolipoprotein a-1 and mimetic peptides |
| JP5719783B2 (ja) | 2009-02-16 | 2015-05-20 | セレニス セラピューティクス ホールディング エスアー | アポリポタンパクａ−ｉ模倣物 |
| US20130137628A1 (en) | 2010-05-11 | 2013-05-30 | Esperion Therapeutics, Inc. | Dimeric Oxidation-Resistant Apolipoprotein A1 Variants |
| HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
| EP3842443B1 (en) | 2013-03-15 | 2025-02-19 | Cerenis Therapeutics Holding SA | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| CA2947127A1 (en) | 2014-05-02 | 2015-11-19 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
| US11752163B2 (en) * | 2020-04-16 | 2023-09-12 | Abionyx Pharma Sa | CER-001 therapy for treating kidney disease |
| MX2022012969A (es) * | 2020-04-16 | 2022-11-09 | Abionyx Pharma Sa | Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos. |
-
2023
- 2023-04-06 CN CN202380044954.XA patent/CN119317440A/zh active Pending
- 2023-04-06 US US18/854,185 patent/US20250255931A1/en active Pending
- 2023-04-06 JP JP2024559383A patent/JP2025512987A/ja active Pending
- 2023-04-06 CA CA3247588A patent/CA3247588A1/en active Pending
- 2023-04-06 AU AU2023251245A patent/AU2023251245A1/en active Pending
- 2023-04-06 IL IL316100A patent/IL316100A/en unknown
- 2023-04-06 WO PCT/IB2023/000183 patent/WO2023194798A1/en not_active Ceased
- 2023-04-06 KR KR1020247036482A patent/KR20240171131A/ko active Pending
- 2023-04-06 EP EP23729835.1A patent/EP4504233A1/en active Pending
-
2024
- 2024-10-03 MX MX2024012302A patent/MX2024012302A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Inhalable stem cell exosomes promote heart repair after myocardial infarction | |
| Wiswell et al. | Bronchopulmonary segmental lavage with surfaxin (KL4-surfactant) for acute respiratory distress syndrome | |
| Jat et al. | Surfactant therapy for bronchiolitis in critically ill infants | |
| Spragg et al. | Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant | |
| Watanabe et al. | Autologous blood transfusion with recombinant human erythropoietin in heart operations | |
| JP2024527340A5 (https=) | ||
| KR102397379B1 (ko) | 자가소화의 치료용의 조성물 | |
| Heptinstall et al. | Peripheral neuritis in systemic lupus erythematosus | |
| JP2022553375A5 (https=) | ||
| JP2025512987A5 (https=) | ||
| Canales Siguero et al. | Paediatric viral myocarditis successfully treated with interferon beta‐1b and corticoids. | |
| JP2002529394A (ja) | 肺サーファクタント組成物を含有する治療セット | |
| Van Zyl et al. | Surfactant treatment before first breath for respiratory distress syndrome in preterm lambs: comparison of a peptide-containing synthetic lung surfactant with porcine-derived surfactant | |
| Lal et al. | Surfactant respiratory therapy using Surfaxin/sinapultide | |
| CN1181826C (zh) | 脂基免疫调节剂组合物 | |
| Zhou | Successful rescue of fulminant myocarditis with mechanical circulatory support and immunosuppression therapy: A case report | |
| Dixon et al. | The relationship of neuropathy to the treatment of tuberculosis with isoniazid | |
| Saboo et al. | Chemical pneumonitis and reactive airways dysfunction syndrome after fumigation exposure to dimethanol and glutaraldehyde: a silent menace unmasked | |
| Çarlı | Oxygen-ozone autohemotherapy in sacroiliitis | |
| CN110294791B (zh) | 具有胆固醇外流活性的抗动脉粥样硬化肽类似物及其应用 | |
| JP2002522507A (ja) | 疾患状態の処置 | |
| Ueno et al. | Morphological abnormalities of erythrocyte membrane in the hereditary neurological disease with chorea, areflexia and acanthocytosis: a study with freeze-fracture electron microscopy | |
| Kopparthy et al. | Red blood cell exchange in a patient with extramedullary hematopoiesis and cor pulmonale secondary to beta thalassemia | |
| Dhamija et al. | Noninvasive ventilation in mild to moderate cases of respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease | |
| US20250177451A1 (en) | Extracellular vesicles for therapy |